Primary Hyperoxaluria Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Precision Biosciences, Chinook Therapeutics, Bridgebio, Oxthera

(MENAFN- GetNews)


"Primary Hyperoxaluria Clinical Trials"DelveInsight's,“Primary Hyperoxyaluria - Pipeline Insight, 2025” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Primary Hyperoxyaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, the Primary Hyperoxaluria pipeline features over 6 key companies actively developing more than 6 therapeutic candidates for the treatment of Primary Hyperoxaluria.

Primary Hyperoxaluria Overview:

Primary hyperoxaluria type 1 (PH1) is a rare inherited disorder caused by a deficiency of the liver enzyme alanine-glyoxylate aminotransferase, leading to overproduction of oxalate. This results in excessive oxalate excretion in urine and the buildup of calcium oxalate in organs, particularly the kidneys. PH1 is the most common and severe form of primary hyperoxaluria, with an estimated prevalence of 1–3 cases per million and an incidence of 1 per 120,000 births annually in Europe.

The condition is marked by the formation of kidney stones, potential kidney damage, and systemic complications if left untreated. Typical symptoms include severe pain in the lower abdomen, groin, or back, discolored urine, painful or frequent urination, and systemic signs such as fever, nausea, and vomiting. Without proper management, PH1 can progress to kidney failure.

Primary hyperoxaluria arises from genetic mutations affecting glyoxylate metabolism: PH1 is linked to the AGXT gene, PH2 to GRHPR, and PH3 to HOGA1. Excess oxalate forms insoluble calcium oxalate deposits in multiple organs, including the kidneys, heart, blood vessels, skin, and bones, resulting in systemic oxalosis. Without effective treatment, the disease can lead to progressive renal and systemic complications.

Request for a detailed insights report on Primary Hyperoxaluria pipeline insights

"Primary Hyperoxaluria Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Hyperoxaluria Therapeutics Market.

Key Takeaways from the Primary Hyperoxaluria Pipeline Report

• DelveInsight's Primary Hyperoxaluria (PH) pipeline report highlights an active landscape, with over 6 companies developing more than 6 therapeutic candidates for the treatment of PH.

• Leading companies-including Precision Biosciences, Chinook Therapeutics, BridgeBio, OxThera, and others-are actively evaluating new therapies to enhance the PH treatment landscape. Notable pipeline candidates in various stages of development include Oxabact and others.

• In September 2023, the FDA approved nedosiran (Rivfloza) for patients aged nine and older with PH1 who have relatively preserved kidney function. This LDHA-targeted small interfering RNA therapy effectively reduces urinary oxalate levels.

• Additionally, lumasiran, an RNA interference therapy, was approved in November 2020 by both the FDA and the European Union for the treatment of PH1 in adults and children. Clinical trials showed that lumasiran significantly lowered urinary oxalate levels in treated patients.

Primary Hyperoxaluria Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Primary Hyperoxaluria Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Primary Hyperoxaluria market.

Download our free sample page report on Primary Hyperoxaluria pipeline insights

Primary Hyperoxaluria Emerging Drugs

• Oxabact: OxThera

Primary Hyperoxaluria Companies

Over six leading companies are actively developing therapies for Primary Hyperoxaluria, with OxThera having a drug candidate that has reached the most advanced stage of development, Phase III.

DelveInsight's report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Primary Hyperoxaluria Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Primary Hyperoxaluria Therapies and Key Companies: Primary Hyperoxaluria Clinical Trials and advancements

Primary Hyperoxaluria Pipeline Therapeutic Assessment

. Primary Hyperoxaluria Assessment by Product Type

. Primary Hyperoxaluria By Stage

. Primary Hyperoxaluria Assessment by Route of Administration

. Primary Hyperoxaluria Assessment by Molecule Type

Download Primary Hyperoxaluria Sample report to know in detail about the Primary Hyperoxaluria treatment market @ Primary Hyperoxaluria Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Primary Hyperoxaluria Current Treatment Patterns

4. Primary Hyperoxaluria - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Primary Hyperoxaluria Late-Stage Products (Phase-III)

7. Primary Hyperoxaluria Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Primary Hyperoxaluria Discontinued Products

13. Primary Hyperoxaluria Product Profiles

14. Primary Hyperoxaluria Key Companies

15. Primary Hyperoxaluria Key Products

16. Dormant and Discontinued Products

17. Primary Hyperoxaluria Unmet Needs

18. Primary Hyperoxaluria Future Perspectives

19. Primary Hyperoxaluria Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Primary Hyperoxaluria Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN28082025003238003268ID1109990310